Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Giuseppe Saglio • 12 Jun 2015
CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials
Resistance/intolerance to second generation TKIs in CML: what to do next?
Giuseppe Saglio • 12 Sep 2018
Prognostic relevance of monocytic switch and future research
Ester Mejstříková et al. • 30 Apr 2021